Sam Roush is the latest Stanford tight end hoping to make his mark on the NFL. Roush was a third-round draft pick Friday in the NFL Draft by the Chicago Bears, No. 69 overall, after playing four ...

Who does not love a good heist movie? The planning, the gathering of the team, the deceit and betrayals and the meticulously laid plans falling to the “best-laid plans” syndrome all immediately take ...

Retail investors are going to drive the S&P 500’s continued gains, according to financial research boutique firm Fundstrat. The S&P 500 SPX hit a new high at the closing bell on Wednesday, reaching ...

The Arknights: Endfield update 1.2 release is almost here. The new update, "At the Wake of Spring," includes a core chapter in the Wuling storyline, a new 6-star electric striker, a multi-character ...

The development team behind a Buzzard Point project at 1 S St. SW is downsizing the first phase, nixing retail and residential units to help make it more appealing to ...

Sam Roush is the latest tight end Stanford is sending to the NFL, and he’s well aware of his predecessors. “I’ve loved every second of it. The whole tight end legacy at Stanford was a huge factor in ...

Drivers on State Highway 6 should prepare for a series of overnight lane closures and a full road closure this week as construction continues on the Big 6 project. “We’ve had a lot of speeding tickets ...

Sam Ryder attended his first Olivier Awards last night, ahead of making his West End debut this summer. He’s set to play the title character in a West End revival of Jesus Christ Superstar at The ...

From tracking KPIs to visualizing trends, Excel offers powerful tools for retail sales analysis. By combining PivotTables, charts, and dashboards, you can turn raw transaction data into actionable ...

Forbes contributors publish independent expert analyses and insights. I do mergers & acquisitions in retail/consumer and write about trends. A decade ago, resale still felt like a bargain hunt: ...

Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going through clinical trials. Now he’s raised some $615 million from top investors ...